Practical considerations for switching β-blockers in heart failure patients

Reviews in Cardiovascular Medicine

Volumn 5, Issue SUPPL. 1, 2004, Pages

  Abraham, William T ^a   Iyengar, Srinivas ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

blockers; Carvedilol; Heart failure; Metoprolol CR XL

Indexed keywords

ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE;

ANTIOXIDANT ACTIVITY; BRADYCARDIA; CLINICAL TRIAL; DIZZINESS; DRUG CLASSIFICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE REMODELING; HUMAN; HYPOTENSION; RECEPTOR BLOCKING; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; HEART FAILURE, CONGESTIVE; HUMANS; PROPANOLAMINES;

EID: 3042538080     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996;94:2807-2816.
2. CIBIS-II. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
3. MERIT-HF. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353:2001-2007.
4. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355.
5. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation. 1996;94:2793-2799.
6. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90:1765-1773.
7. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 1997;30:27-34.
8. Lechat P, Packer M, Chalon S, et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation. 1998;98:1184-1191.
9. Vantrimpont P, Rouleau JL, Wun CC, et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol. 1997;29:229-236.
10. Cleland JG, McGowan J, Clark A, Freemantle N. The evidence for beta blockers in heart failure. BMJ. 1999;318:824-825.
11. HFSA. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches. J Card Fail. 1999;5:357-382.
12. Packer M, Cohn JN, on behalf of the Steering Committee and Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensus recommendations for the management of chronic heart failure. Am J Cardiol. 1999;83:1A-38A.
13. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
14. The Capricorn Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-1390.
15. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group [published erratum appears in Lancet 1990;336(8716):698]. Lancet. 1990; 336:1-6.
16. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-1667.
17. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol. 1997;80:26L-40L.
18. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation. 2000; 101:558-569.
19. Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis. 1998;41:39-52.
20. Abraham WT, Singh B. Ischemic and nonischemic heart failure do not require different treatment strategies. J Cardiovasc Pharmacol. 1999;33(Suppl 3):S1-S7.
21. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
22. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure [editorial]. J Am Coll Cardiol. 1992;20:248-254.
23. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205-211.
24. Swedberg K, Viquerat C, Rouleau JL, et al. Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. Am J Cardiol. 1984;54:783-786.
25. Hasking GJ, Esler MD, Jennings GL, et al. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73:615-621.
26. Kaye DM, Lefkovits J, Jennings GL, et al. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol. 1995;26:1257-1263.
27. McDonald KM, Rector T, Carlyle PF, et al. Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage. J Am Coll Cardiol. 1994;24:1762-1768.
28. Patten RD, Udelson JE, Konstam MA. Ventricular remodeling and its prevention in the treatment of heart failure. Curr Opin Cardiol. 1998;13:162-167.
29. Hall SA, Cigarroa CG, Marcoux L, et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol. 1995;25:1154-1161.
30. Mann DL, Kent RL, Parsons B, Cooper G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85: 790-804.
31. Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in beta 1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA. 1999;96:7059-7064.
32. Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol. 1997;80:15L-25L.
33. Lowes BD, Minobe W, Abraham WT, et al. Changes in gene expression in the intact human heart. Down-regulation of alphamyosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest. 1997; 100:2315-2324.
34. Kanai AJ, Mesaros S, Finkel MS, et al. Beta-adrenergic regulation of constitutive nitric oxide synthase in cardiac myocytes. Am J Physiol. 1997;273:C1371-C1377.
35. Zierhut W, Zimmer HG. Significance of myocardial a- and b-adrenoceptors in catecholamine-induced cardiac hypertophy. Circ Res. 1989;65:1417-1425.
36. Simons M, Downing SE. Coronary vasoconstriction and catecholamine cardiomyopathy. Am Heart J. 1985;109:297-304.
37. Molina-Viamonte V, Anyukhovsky EF, Rosen MR. An alpha-1-adrenergic receptor subtype is responsible for delay after depolarizations and triggered activity during simulated ischemia and reperfusion of isolated canine Purkinje fibers. Circulation. 1991;84:1732-1740.
38. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation. 1998;98:1329-1334.
39. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation. 1996; 94:2285-2296.
40. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 1975;37:1022-1036.
41. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet. 1979;1:1374-1376.
42. Bristow MR, Ginsburg R, Umans V, et al. Beta-1 and beta-2 adrenergic-receptors subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta-1 receptor down-regulation in heart failure. Circ Res. 1986;59:297-309.
43. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94:2817-2825.
44. Heilbrunn SM, Shah P, Bristow MR, et al. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989;79:483-490.
45. Hall JA, Kaumann AJ, Brown MJ. Selective beta 1-adrenoceptor blockade enhances positive inotropic responses to endogenous catecholamines mediated through beta 2-adrenoceptors in human atrial myocardium. Circ Res. 1990;66:1610-1623.
46. Billman GE, Castillo LC, Hensley J, et al. Beta 2-adrenergic receptor antagonists protect against ventricular fibrillation: in vivo and in vitro evidence for enhanced sensitivity to beta 2-adrenergic stimulation in animals susceptible to sudden death. Circulation. 1997;96:1914-1922.
47. Schomig A, Richardt G, Kurz T. Sympatho-adrenergic activation of the ischemic myocardium and its arrhythmogenic impact. Herz. 1995;20:169-186.
48. Bristow MR, Roden RL, Lowes BD, et al. The role of third-generation beta-blocking agents in chronic heart failure [published erratum appears in Clin Cardiol 1999 Mar;22(3): following table of contents]. Clin Cardiol. 1998;21:I3-I13.
49. Ruffolo RR Jr, Gellai M, Hieble JP, et al. The pharmacology of carvedilol. Eur J Clin Pharmacol. 1990;38(Suppl 2):S82-S88.
50. Gilbert EM, Anderson JL, Deitchman D, et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med. 1990;88:223-229.
51. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995;25:1225-1231.
52. Metra M, Giubbini R, Nodari S, et al. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation. 2000;102:546-551.
53. Di Lenarda A, Sabbadini G, Salvatore L, et al. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group. J Am Coll Cardiol. 1999;33:1926-1934.
54. Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J. 2001;141:899-907.
55. Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 1992;263:92-98.
56. Dandona P, Karne R, Ghanim H, et al. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation. 2000;101:122-124.
57. Senior R, Basu S, Kinsey C, et al. Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. Am Heart J. 1999;137:646-652.
58. Ohlstein EH, Douglas SA, Sung CP, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA. 1993;90:6189-6193.
59. Sung CP, Arleth AJ, Ohlstein EH. Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol. 1993;21:221-227.
60. Yue TL, Ma XL, Wang X, et al. Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res. 1998;82:166-174.
61. Feuerstein G, Yue TL, Ma X, Ruffolo, RR. Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis. 1998;41:17-24.
62. Saijonmaa O, Metsarinne K, Fyhrquist F. Carvedilol and its metabolites suppress endothelin-1 production in human endothelial cell culture. Blood Press. 1997;6:24-28.
63. Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET) randomized controlled trial. Lancet. 2003;362:7-13.
64. Metra M, Dilenarda A, Hanrath P, et al. Blood pressure changes do not influence the beneficial effects of carvedilol compared to metoprolol in the patients with heart failure: Results from the COMET (Carvedilol or Metoprolol European Trial). Poster number 1012-103, Presented at the 53rd Annual Scientific Session of the American College of Cardiology, New Orleans, LA. March 2004.
65. Metra M, Cleland JGF, DiLenarda A, et al. Lack of heart rate effects on the mortality benefits of carvedilol compared to metoprolol in the patients with heart failure: Results from the Carvedilol or Metoprolol Eurpean Trial (COMET). Poster number 1012-121, Presented at the 53rd Annual Scientific Session of the American College of Cardiology, New Orleans, LA. March 2004.
66. Poole-Wilson PA, Swedberg K, Cleland JFG, et al. A comparison of adverse events occurring with carvedilol or metoprolol in the treatment of heart failure: Results from COMET. Presented at the 53rd Annual Scientific Session of the American College of Cardiology, New Orleans, LA. March 2004.
67. Remme WJ, Cleland JG, DiLenarda A, et al. Carvedilol better protects against vascular events than metoprolol in heart failure: Results from COMET. Presented at the 53rd Annual Scientific Session of the American College of Cardiology, New Orleans, LA. March 2004.
68. Abraham WT, Tsvetkova T, Lowes BD, et al. Carvedilol improves renal hemodynamics in patients with chronic heart failure. Circulation. 1998;98:I-378-I-379.
69. Fassbinder W, Quarder O, Waltz A. Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicentre randomised study [see comments]. Int J Clin Pract. 1999;53:519-522.
70. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens. 1998;11:1258-1265.
71. Marchi F, Ciriello G. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol. Adv Ther. 1995;12:212-221.
72. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med. 1997;126:955-959.
73. Nagakawa Y, Akedo Y, Kaku S, Orimo H. Effects of carvedilol on common carotid arterial flow, peripheral hemodynamics, and hemorheologic variables in hypertension. Eur J Clin Pharmacol. 1990;38(Suppl 2):S115-S119.
74. Maack C, Elter T, Nickenig G, et al. Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure. J Am Coll Cardiol. 2001;38:939-946.